<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dement Neuropsychol</journal-id><journal-id journal-id-type="iso-abbrev">Dement Neuropsychol</journal-id><journal-id journal-id-type="publisher-id">dn</journal-id><journal-title-group><journal-title>Dementia &#x00026; Neuropsychologia</journal-title></journal-title-group><issn pub-type="ppub">1980-5764</issn><publisher><publisher-name>Associa&#x000e7;&#x000e3;o de Neurologia Cognitiva e do
Comportamento</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29213808</article-id><article-id pub-id-type="pmc">5619340</article-id><article-id pub-id-type="doi">10.1590/S1980-57642012DN06040012</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Reassessment of the dementia diagnosis of Alzheimer's disease in
patients enrolled on the cholinesterase inhibitors dispensation
program</article-title><trans-title-group xml:lang="pt"><trans-title>REAVALIA&#x000c7;&#x000c3;O DO DIAGN&#x000d3;STICO DE DEM&#x000ca;NCIA
DA DOEN&#x000c7;A DE ALZHEIMER EM PACIENTES INSCRITOS NO PROGRAMA DE
DISPENSA&#x000c7;&#x000c3;O DE INIBIDORES DE COLINESTERASE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Piovesana</surname><given-names>Magda Cristina Flaitt Sanches</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Garcia</surname><given-names>F&#x000fa;lvio Rog&#x000e9;rio</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Carrasco</surname><given-names>K&#x000e1;tia G.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tognola</surname><given-names>Waldir Antonio</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Enfermeira, Mestre em Medicina e Ci&#x000ea;ncias da Sa&#x000fa;de,
Faculdade de Medicina de S&#x000e3;o Jos&#x000e9; do Rio Preto, SP, Brazil.</aff><aff id="aff2">
<label>2</label>M&#x000e9;dico Contratado, Faculdade de Medicina de S&#x000e3;o
Jos&#x000e9; do Rio Preto, SP, Brazil.</aff><aff id="aff3">
<label>3</label>Psic&#x000f3;loga, Mestranda em Medicina e Ci&#x000ea;ncias da
Sa&#x000fa;de, Faculdade de Medicina de S&#x000e3;o Jos&#x000e9; do Rio Preto, SP,
Brazil.</aff><aff id="aff4">
<label>4</label>Professor em&#x000e9;rito da Faculdade de Medicina de S&#x000e3;o
Jos&#x000e9; do Rio Preto, SP, Brazil.</aff><author-notes><corresp id="c1"><bold>Magda Cristina Flaitt Sanches Piovesana</bold>. Rua
Lav&#x000ed;nia, 150 / Apto 01 &#x02013; 15806-300 Catanduva SP &#x02013; Brasil. E- mail:
<email>magdacfsp@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Oct-Dec</season><year>2012</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2012</year></pub-date><volume>6</volume><issue>4</issue><fpage>270</fpage><lpage>275</lpage><history><date date-type="received"><day>03</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>04</day><month>11</month><year>2012</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>Reassess the diagnosis of Alzheimer's Disease (AD) in patients treated with
anti-cholinesterases dispensed by High Cost Drug stores (Exceptional Drugs
Program).</p></sec><sec><title>Methods</title><p>A prospective study to reassess the diagnosis of probable Alzheimer's Disease
was conducted (AD). The patients were submitted to the protocol of dementia
investigation at the Neurogeriatric Outpatient Clinic of the Teaching
Hospital de Base de S&#x000e3;o Jos&#x000e9; do Rio Preto. Groups were
classified using the criteria of the National Institute of Neurologic and
Communicative Diseases and Vascular Cerebral Accident and Alzheimer Disease
Related Association (NINCDS-ADRDA). The study was completed by applying the
Disability Assessment for Dementia (DAD). The significance level was set at
5%.</p></sec><sec><title>Results</title><p>106 patients participated, selected randomly from a group of 390 patients
contacted when receiving their medication at the High Cost Drug store. Two
groups were formed: the first, containing 52 patients who fulfilled criteria
for AD (FC Group); and a second, with 54 patients not fulfilling criteria
(NFC). The FC Group had older age, worse performance on the Mini-Mental
State Exam (MMSE) and poorer performance on the DAD. Also, treatment time
was longer and drugs doses higher in the FC Group.</p></sec><sec><title>Conclusion</title><p>Study results showed a high number of patients using anti-cholinesterases
that did not fulfill the diagnosis criteria for probable AD. Comparison of
the two groups revealed different behavior between them, corroborating the
hypothesis of inadequate inclusion of the NFC Group patients in the
Exceptional Drugs Program.</p></sec></abstract><trans-abstract xml:lang="pt"><sec><title>Objetivo</title><p>Reavaliar o diagn&#x000f3;stico de Doen&#x000e7;a de Alzheimer (DA) nos
pacientes em tratamento com anticolines-ter&#x000e1;sicos dispensados pelas
farm&#x000e1;cias de alto custo (Programa de Medicamentos Excepcionais).</p></sec><sec><title>M&#x000e9;todos</title><p>Estudo prospectivo, para reavalia&#x000e7;&#x000e3;o do diagn&#x000f3;stico de
Doen&#x000e7;a de Alzheimer (DA) prov&#x000e1;vel. Os pacientes foram
submetidos ao protocolo de investiga&#x000e7;&#x000e3;o de dem&#x000ea;ncias do
ambulat&#x000f3;rio de Neurogeriatria do Hospital de Base de S&#x000e3;o
Jos&#x000e9; do Rio Preto. Utilizou-se para classifica&#x000e7;&#x000e3;o nos
grupos crit&#x000e9;rios do Instituto Nacional de Doen&#x000e7;as
Neurol&#x000f3;gicas e Comunicativas e Acidente Vascular Cerebral e
Associa&#x000e7;&#x000e3;o da Doen&#x000e7;a de Alzheimer e Doen&#x000e7;as
Relacionadas (NINCDS-ADRA). Completou-se o estudo utilizando-se a Escala
para Avalia&#x000e7;&#x000e3;o de Incapacidades na Dem&#x000ea;ncia (DAD). Foi
estabelecido o n&#x000ed;vel de signific&#x000e2;ncia em 5%.</p></sec><sec><title>Resultados</title><p>Participaram 106 pacientes, selecionados aleatoriamente de um grupo de 390
pacientes contactados quando recebiam o medicamento na farm&#x000e1;cia de
alto-custo. Obtiveram-se dois grupos: o primeiro que preencheu
crit&#x000e9;rios para DA (Grupo PC), que incluiu 52 pacientes e o segundo
grupo o qual n&#x000e3;o preencheu crit&#x000e9;rios (Grupo NPC) com 54
pacientes. O Grupo PC apresentou: idade mais elevada, pior performance no
Mini Exame do Estado Mental (MEEM) e desempenho inferior na DAD. O tempo de
tratamento era maior e doses mais elevadas dos medicamentos no Grupo PC.</p></sec><sec><title>Conclus&#x000e3;o</title><p>De acordo com os resultados do estudo, observou-se um grande n&#x000fa;mero de
pacientes utilizando anticolinester&#x000e1;sicos que n&#x000e3;o preencheram
os crit&#x000e9;rios diagn&#x000f3;sticos para DA prov&#x000e1;vel. Na
compara&#x000e7;&#x000e3;o dos dois grupos observou-se comportamento diferente
dos mesmos, que permitiram corroborar com a hip&#x000f3;tese de
inclus&#x000e3;o inadequada dos pacientes do Grupo NPC no Programa de
Medicamentos Excepcionais.</p></sec></trans-abstract><kwd-group><kwd>Alzheimer's disease</kwd><kwd>anti-cholinesterases</kwd><kwd>diagnosis assessment</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>The growth of the elderly population in clearly one of the most noteworthy current
phenomena, with varied and intricate social consequences. This shift fosters the
incidence and prevalence of degenerative chronic diseases associated to aging, among
which include those causing dementia.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref></sup> Epidemiologic
studies indicate a high prevalence of dementia in elderly people, representing
unequivocal data proving that age is a significant risk factor.<sup><xref rid="r3" ref-type="bibr">3</xref></sup></p><p>Alzheimer's Disease (AD) is the main cause of cognitive decline in the elderly,
representing more than half of all dementia cases.<sup><xref rid="r4" ref-type="bibr">4</xref></sup> In a population-based study carried out in Catanduva
city, in S&#x000e3;o Paulo State (SP), a 7.1% prevalence of dementia cases was
observed in individuals aged 65 years or older with AD being the most frequent
etiology, found in 55.1% of the dementia cases.<sup><xref rid="r5" ref-type="bibr">5</xref></sup></p><p>There is currently no etiologic treatment for AD available, with treatment comprising
pharmacological strategies based on the presupposition of cholinergic
deficit.<sup><xref rid="r4" ref-type="bibr">4</xref></sup> The main aim is
to regulate this in the central nervous system with cholinesterase inhibitors
(I-ChE).<sup><xref rid="r6" ref-type="bibr">6</xref></sup> The Brazilian
Academy of Neurology recommends treatment with cholinesterase inhibitors as
effective for Alzheimer's disease.<sup><xref rid="r7" ref-type="bibr">7</xref></sup>
Currently, three I-ChEs are fully approved for clinical use: Rivastigmine,
Galantamine and Donepezil.<sup><xref rid="r8" ref-type="bibr">8</xref></sup> In the
medical literature there are a number of studies demonstrating the efficiency of
cholinesterase inhibitors in AD,<sup><xref rid="r9" ref-type="bibr">9</xref>-<xref rid="r11" ref-type="bibr">11</xref></sup> hence the government program which
makes this medication available to the population.</p><p>Ensuring access to medications is a complementary and essential part of an adequate
health care policy. The Unified Health System (SUS) has been engaged in providing
free high-cost medications. These drugs, also called "exceptional" are included
under the Exceptional Drugs Program.<sup><xref rid="r12" ref-type="bibr">12</xref></sup></p><p>In order to provide the population with treatment, the Ministry of Health established
the "Assistance Program for People with Alzheimer's disease", the Protocol Clinical
Guideline for the treatment of Alzheimer's disease, included the cholinesterase
inhibitors Rivastig-mine, Galantamine and Donepezil in the list of high-cost
medications, and determined criteria for inclusion/ exclusion of patients for
treatment, diagnostic criteria, recommended a therapeutic regimen and mechanisms for
monitoring and evaluating treatment.<sup><xref rid="r13" ref-type="bibr">13</xref></sup></p><p>For inclusion in this protocol patients must: provide an assessment of a neurologist
and/or psychiatrist and/ or geriatrician; fulfill the clinical criteria of dementia
due to possible or probable Alzheimer's Disease, have undergone the Mini Mental
State Exam (MMSE) with a score of between 12 and 24 for patients schooled beyond
primary education, and between 8 and 17 for those with up to primary education;
Individuals with a Clinical Dementia Rating (CDR) of 1 or 2 (moderate or mild
dementia) will not be included in this Treatment protocol nor will patients
exhibiting at least one of the following: poor adherence to the treatment, evidence
of non-compensated simultaneous organic or metabolic cerebral lesions, severe
cardiac insufficiency or cardiac arrhythmia, parkinsonian syndrome, diarrhea, and
peptic disease without response to treatment.<sup><xref rid="r8" ref-type="bibr">8</xref></sup></p><p>As criteria to discontinue the treatment, the following variables will be checked:
absence of improvement or steady deterioration of the patient's clinical picture on
reassessment three or four months after the beginning of treatment; even for those
on continued treatment, treatment must only be maintained while the MMSE score
remains above 12 (twelve) for patients with greater than primary education and above
8 (eight) for patients with incomplete primary education, as there has been no
evidence of treatment benefit with fewer years of education and thus treatment
should be suspended.<sup><xref rid="r8" ref-type="bibr">8</xref></sup></p><p>Due to the social relevance of AD, halting disease evolution is a major priority. The
Exceptional Drugs Program makes the anti cholinesterases available for use in the
initial and intermediate phases of the disease. No publications evaluating the
effectiveness of the anti cholinesterases dispensation program are available.
Evidence from clinical practice has shown that some patients using the drugs did not
fulfill the diagnosis criteria for AD, generating unnecessary cost.</p><p>The aim of this study was to reassess the diagnosis of patients under the Exceptional
Drugs Program and to demonstrate that the group with confirmed AD differed to the
group without AD.</p></sec><sec sec-type="methods"><title>METHODS</title><p>The study was performed at the Neurogeriatric Outpatient Clinic, of the Medical
School of S&#x000e3;o Jos&#x000e9; do Rio Preto - FAMERP and Hospital de Base.</p><p>Patients living in the municipality of S&#x000e3;o Jos&#x000e9; do Rio Preto, SP -
Brazil were included in the study. They were enrolled in the "Assistance Program for
Alzheimer's Disease Carriers"; supported by the service to provide medication of
specialized composition from the Pharmaceutical Attendance Program (High
Cost);<sup><xref rid="r14" ref-type="bibr">14</xref></sup> and in use of
anti cholinesterases for at least three months. All subjects signed the free
informed consent form after agreeing to participate in this scientific
investigation.</p><p>In order to reassess the diagnosis of probable AD, the following steps were
followed:</p><p><bold>PHASE I - Sample selection.</bold> In this prospective study, the sample
selection occurred in the period between May 2008 and February 2010. During this
time, the High Cost Drug stores attended an average of 835 patients a month. During
the data collection, of the 390 patients who were initially contacted, only 106
patients participated in all the phases of the study.</p><p>Patients were invited to participate in the study during the monthly dispensing of
the drug at the High Cost Drug stores, and in most cases the patients were
represented by a family member.</p><p><bold>PHASE II - Diagnosis reassessment.</bold> The patients were submitted to the
dementia protocol of the Neurogeriatric Outpatient Clinic of Hospital de Base, which
includes clinical assessment, review of the Mini-Mental State Exam (MMSE),<sup><xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref></sup> laboratory and imaging exams, following IDC-10<sup><xref rid="r17" ref-type="bibr">17</xref></sup> considering those who already had
exams.</p><p>To certify the AD diagnosis, patients were assessed by two neurologists and a
psychologist, using the National Institute of Neurologic and Communicative Diseases
and Vascular Cerebral Accident (NINCDS) and Alzheimer Disease Related Association
(ADRDA)<sup><xref rid="r18" ref-type="bibr">18</xref></sup> criteria, which
allows the classification of dementia of the Alzheimer type (AD) into three
different levels: definitive AD - requires the presence of probable or possible AD
with neuropathological confirmation; probable AD - this is the chosen diagnosis when
the dementia syndrome has slow and progressive onset and when other etiological
factors have been excluded; possible AD -the available alternative to classify the
disease when the clinical picture is atypical or there is a concomitant physical
condition which may also cause dementia.</p><p>After this analysis, patients were categorized into two groups, those who fulfilled
the criteria (FC Group), and those who did not fulfill the diagnostic criteria (NFC
Group) for AD. The group that did not fulfill the criteria was not studied further
and included several clinical situations.</p><p><bold>PHASE III - Group analysis.</bold> FC and NFC Groups were compared to better
reassess the AD diagnosis. This was done based on Sociodemographic characteristics
such as age, sex, education as well as Clinical characteristics: MMSE values,
treatment duration, prescribed types and doses of anti-cholinesterases, plus a scale
for the Disability of Assessment for Dementia (DAD) which evaluates basic,
instrumental and leisure activities. The total score is 100 and lower values denote
a higher hindrance in activities of daily living<sup><xref rid="r19" ref-type="bibr">19</xref>-<xref rid="r23" ref-type="bibr">23</xref></sup>.</p><p>Due to ethical reasons, those who took the patient to the Exceptional Drugs Program
have not been identified, and the study results have been presented to the program
manager in a general sense.</p><p><bold>Statistical analysis.</bold> The statistical analysis was performed by means of
tables of crossed frequencies to assess association between the group that fulfilled
the criteria and the group that did not fulfill criteria for Alzheimer's disease,
according to the classified qualitative or quantitative variables.</p><p>The Chi-square test was used to measure the association of categorical variables
(gender, age group, educational level, length of treatment, anticholines-terase
prescribed, MMSE, DAD) along with Fisher's exact test.</p><p>The medians were submitted to the Kruskal-Wallis test to determine the level of
statistical significance. The Student's <italic>t</italic>-test was used to compare
the variables (age and age versus gender).</p><p>The level of significance was set at 5% (p&#x0003c;0.05).</p><p><bold>Ethical approach.</bold> This study was approved by the Human Research Ethics
Committee under protocol #2644/2008.</p></sec><sec sec-type="results"><title>RESULTS</title><p>One hundred and six patients participated in the study. Subjects were classified into
either the FC Group, when they fulfilled the criteria for AD, or into the NFC Group
when they did not. According to the method used, 52 (49%) patients were classified
as probable AD.</p><p><bold>Socio-demographic characteristics of the groups.</bold> In the FC Group, there
was a predominance of women: 39 women (75%) and 13 men (25%) whereas in the NFC
Group, there were 29 women (54%) and 25 men (46%) (<xref ref-type="table" rid="t1">Table 1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Distribution of patients by age, education, and gender according to
fulfillment (FC) or non-fulfillment (NFC) of Alzheimer's Disease (AD)
criteria.</p></caption><table frame="hsides" rules="rows"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" style="background-color:#d2d3d5" colspan="1">&#x000a0;</th><th align="center" rowspan="2" style="background-color:#d2d3d5" colspan="1">n</th><th align="center" rowspan="2" style="background-color:#d2d3d5" colspan="1">Age in
years (mean)</th><th align="center" rowspan="2" style="background-color:#d2d3d5" colspan="1">Education up to 3 years</th><th align="center" colspan="2" style="background-color:#d2d3d5" rowspan="1">Gender
(%)</th></tr><tr><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1"><bold>Male</bold></th><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1"><bold>Female</bold></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">FC Group</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">77.8</td><td align="center" rowspan="1" colspan="1">77.0</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">75</td></tr><tr><td align="left" rowspan="1" colspan="1">NFC Group</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">74.2</td><td align="center" rowspan="1" colspan="1">68.0</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">54</td></tr></tbody></table></table-wrap><p>Age in the FC Group ranged from 60 to 94 years (mean=77.8 years old, standard
deviation (sd)=7. 95, mode (m)=78 years). In the NFC Group, age ranged from 52 to 88
years (mean=74.2 years old, sd=7.74, m =74 years). The statistical analysis showed
that the mean age of those who did not have confirmed AD was lower than the group
that had confirmed AD (t-Test=0; p=0.019) (<xref ref-type="table" rid="t1">Table
1</xref>).</p><p>Analysis of both FC and NFC groups according to sex and age revealed no significant
evidence of differences in mean age and sex of patients with AD confirmation
p=0.278).</p><p>In the FC Group , 41 patients (77%) had less than three years of education. In the
NFC Group , 37 (68%) had education of up to 3 years. The statistical analysis showed
that the variable of educational level had no positive association between the FC
and NFC Groups for AD. (Chi-Square=5.900; p=0.207) (<xref ref-type="table" rid="t1">Table 1</xref>).</p><p><bold>Clinical characteristics.</bold> It was observed that 44 (85%) patients from
the FC Group had low MMSE while in the NFC Group 27 (50%) had normal values and 27
(50%) low scores. Although this group of patients showed cognitive deficit, it was
not characterized as AD. The analysis showed evidence of a positive association
between low MMSE and AD confirmation (Chi-Square =14.35; p=0.000).</p><p>All patients of the FC Group had been undergoing treatment with anti-cholinesterases
for more than six months, and 33% had been undergoing the treatment for between 13
and 24 months. In the NFC Group, 13% of patients had been on anticholinesterase
treatment for less than 6 months whereas 41% had been receiving anticholinesterase
for between 6 and 12 months. A correlation was observed between longer time on
treatment and confirmation of AD diagnosis (Chi-Square: 20.009) (<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Comparison of groups according to AD treatment duration.</p></caption><table frame="hsides" rules="rows"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="1%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" style="background-color:#d2d3d5" colspan="1">Treatment duration (months)</th><th align="center" colspan="2" style="background-color:#d2d3d5" rowspan="1">FC
Group</th><th align="center" rowspan="2" style="background-color:#d2d3d5" colspan="1">&#x000a0;</th><th align="center" colspan="2" style="background-color:#d2d3d5" rowspan="1">NFC
Group</th><th align="center" rowspan="2" style="background-color:#d2d3d5" colspan="1">p</th></tr><tr><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1"><bold>n</bold></th><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1"><bold>%</bold></th><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1"><bold>n</bold></th><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1"><bold>%</bold></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;6</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">12.9</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">6 to 12</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">17.3</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">40.7</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">13 to 24</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">32.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">22.2</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">25 to 36</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">17.3</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">14.8</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">37 to 48</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">9.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1.8</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">49 or +</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">23.0</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">7.4</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><p>In the present study, the pharmacological interventions for AD were based on the
three available cholin-esterase inhibitors: Rivastigmine, Galantamine and Donepezil.
In the FC Group, 44% of patients used Riv-astigmine, 44% Galantamine and 11%
Donepezil. It was observed that the medications were prescribed in effective or full
doses. For the NFC Group , 59% of patients used Rivastigmine, 35% Galantamine and 5%
Done-pezil. It is noteworthy that the lowest doses of 1.5 mg-Rivastigmine were being
administered to 18 patients (33%). (Chi Square =13. 5 and p=0.13) (<xref ref-type="table" rid="t3">Table 3</xref>).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Pharmacological treatment with anticholinesterases, according to drug type
and dose in Groups (FC and NFC).</p></caption><table frame="hsides" rules="rows"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#d2d3d5" rowspan="1" colspan="1">Drug</th><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1">Dose</th><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1">FC Group %</th><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1">NFC Group %</th><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Rivastigmine</td><td align="center" rowspan="1" colspan="1">1.5 mg</td><td align="center" rowspan="1" colspan="1">7.6</td><td align="center" rowspan="1" colspan="1">33.3</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Rivastigmine</td><td align="center" rowspan="1" colspan="1">2 mg</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">5.5</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Rivastigmine</td><td align="center" rowspan="1" colspan="1">3 mg</td><td align="center" rowspan="1" colspan="1">15.3</td><td align="center" rowspan="1" colspan="1">9.2</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Rivastigmine</td><td align="center" rowspan="1" colspan="1">4.5 mg</td><td align="center" rowspan="1" colspan="1">9.6</td><td align="center" rowspan="1" colspan="1">5.5</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Rivastigmine</td><td align="center" rowspan="1" colspan="1">6 mg</td><td align="center" rowspan="1" colspan="1">9.6</td><td align="center" rowspan="1" colspan="1">5.5</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Galantamine</td><td align="center" rowspan="1" colspan="1">8 mg</td><td align="center" rowspan="1" colspan="1">11.5</td><td align="center" rowspan="1" colspan="1">12.9</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Galantamine</td><td align="center" rowspan="1" colspan="1">16 mg</td><td align="center" rowspan="1" colspan="1">15.3</td><td align="center" rowspan="1" colspan="1">9.2</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Galantamine</td><td align="center" rowspan="1" colspan="1">24 mg</td><td align="center" rowspan="1" colspan="1">17.3</td><td align="center" rowspan="1" colspan="1">12.9</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Donepezil </td><td align="center" rowspan="1" colspan="1">5 mg</td><td align="center" rowspan="1" colspan="1">7.6</td><td align="center" rowspan="1" colspan="1">3.7</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Donepezil </td><td align="center" rowspan="1" colspan="1">10 mg</td><td align="center" rowspan="1" colspan="1">3.8</td><td align="center" rowspan="1" colspan="1">1.85</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><p>On the evaluation according to the DAD scale, whose results ranged from zero percent
(greater functional dependence) to a hundred percent (greater functional
independence); the median score of the FC Group was 25.5 (mean=29.7, sd=25.9, m=5).
In the NFC Group, the median DAD score was 76.5 (mean=66.1, sd =35.34, m=100). The
statistical analysis showed evidence of the median for performance of daily
activities, i.e. this value was lower in the confirmed AD group. (Chi-square: 21.74;
p=0.000 and CI=95% (-76.0;-37.0) (<xref ref-type="table" rid="t4">Table
4</xref>).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Comparison between FC and NFC Groups, according to performance on DAD.</p></caption><table frame="hsides" rules="rows"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="1%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" style="background-color:#d2d3d5" colspan="1">DAD</th><th align="center" colspan="2" style="background-color:#d2d3d5" rowspan="1">FC Group </th><th align="center" rowspan="2" style="background-color:#d2d3d5" colspan="1">&#x000a0;</th><th align="center" colspan="2" style="background-color:#d2d3d5" rowspan="1">NFC
Group </th><th align="center" rowspan="2" style="background-color:#d2d3d5" colspan="1">p</th></tr><tr><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1"><bold>%</bold></th><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1"><bold>Median</bold></th><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1"><bold>%</bold></th><th align="center" style="background-color:#d2d3d5" rowspan="1" colspan="1"><bold>Median</bold></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">25.5</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">76.5</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">50 to100%</td><td align="center" rowspan="1" colspan="1">24.8</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">72.1</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">0 to 49%</td><td align="center" rowspan="1" colspan="1">75.0</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">27.6</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>AD is an important social economic problem, and the government has established the
dispensation of medications for its treatment. However, it has been noted that many
patients who were taking the anti-cholinesterases did not fulfill the diagnostic
criteria, implying an unnecessary cost since these are high cost medications. The
evidence in scientific publications points to the effectiveness of the treatment,
but there is a lack of studies analyzing diagnosis reassessment.</p><p>Application of the protocol and confirmation criteria for AD resulted in 2 groups of
patients: those who fulfilled the criteria and those who did not. The NFC Group was
heterogeneous with several diagnoses, including age-related cognitive deficit,
vascular dementia, depression, or other psychiatric and clinical manifestations,
where this group was not relevant to the aim of this study. However, comparison of
both groups seemed appropriate, for they originally formed the same group.</p><p>Forty-nine percent of patients had probable AD diagnosis, and the remaining 51% did
not fulfill the criteria for AD. Anuncia&#x000e7;&#x000e3;o et al. 24 found similar
results in a study performed in Rio de Janeiro. They showed that only 50% of the
patients diagnosed with AD fulfilled fully integrated requirements of ICD-10, thus
confirming the great difficulty in establishing the diagnosis for AD.<sup><xref rid="r5" ref-type="bibr">5</xref></sup></p><p>Comparing both groups, the average age of the FC Group was higher than the NFC group,
and according to review studies the incidence of Alzheimer Disease rises with
advancing age.<sup><xref rid="r25" ref-type="bibr">25</xref>-<xref rid="r27" ref-type="bibr">27</xref></sup> Gender analysis showed that in the FC Group there
was a high prevalence of females (75%) with a practically similar pattern in the NFC
Group. Several other studies have shown a predominance of women with AD,<sup><xref rid="r28" ref-type="bibr">28</xref>,<xref rid="r29" ref-type="bibr">29</xref></sup> but according to the authors concerned, this gender
difference could have been due to longevity of women and not to any specific risk
factor linked to sex.<sup><xref rid="r30" ref-type="bibr">30</xref></sup> Education
was poor in both FC and NFC Group, showing that both groups were equivalent for
schooling.</p><p>To complete the study and certify that reassessment was valid, MMSE, time in use of
medication, prescribed doses and DAD in both groups were compared. Comparison of
MMSE in both groups revealed that patients from the FC Group had lower scores than
those from the NFC Group. Concerning medication use, patients from the FC Group used
higher doses for a longer period. In this study, better performance was observed by
patients in the Group NFC than in the FC Group on the activities evaluated in the
DAD, although in both groups high values of standard deviation were found.</p><p>These data corroborate the hypothesis that there were indeed two distinct groups,
with the second not meeting the diagnostic criteria, exhibiting much higher MMSE
scores, sub therapeutic doses and a DAD performance closer to normal. As this was a
pilot trial of a regional nature, there was probably some interference, a theory
warranting further studies.</p><p>According to the results of this study, a great number of patients using
anti-cholinesterase were observed that did not fulfill the diagnosis criteria for
AD, thereby resulting in a great negative impact both for the patient, his/her
family as well as society.</p><p>When the two groups were compared, different behaviour between them was observed,
thus corroborating the hypothesis of inadequate inclusion of patients in the NFC
under the Exceptional Drugs Program.</p><p>As AD diagnosis is based on memory related deficits, the NFC Group may have included
patients at initial phases of the disease and also those with other diagnoses such
as age-related cognitive deficit, vascular dementia, depression and other
psychiatric manifestations, where systematized studies and follow-ups of these
patients would help characterize the underlying disease.</p><p>Due to the symptomatology dynamics of the disease, while on the one hand treatment
may be postponed with anti cholinesterases, on the other, patients may be
precociously introduced into taking the drug. The results of this study suggest that
more comprehensive criteria should be adopted in the inclusion of patients onto the
Exceptional Drugs Program.</p><p>In short, it has been concluded that in the dispensation of medications, 51% of
patients did not fulfill the AD diagnostic criteria, a finding reinforced on
analysis of the variables MMSE, dose, time in use of medication and scores on the
DAD.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>Disclosure: The authors report no conflicts of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalache</surname><given-names>A</given-names></name><name><surname>Veras</surname><given-names>RP</given-names></name><name><surname>Ramos</surname><given-names>LR</given-names></name></person-group><article-title>O envelhecimento da popula&#x000e7;&#x000e3;o mundial: um desafio
novo</article-title><source>Rev Sa&#x000fa;de P&#x000fa;bl</source><year>1987</year><volume>21</volume><fpage>200</fpage><lpage>210</lpage></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilela</surname><given-names>LP</given-names></name><name><surname>Caramelli</surname><given-names>P</given-names></name></person-group><article-title>A Doen&#x000e7;a de Alzheimer na vis&#x000e3;o de familiares de
pacientes</article-title><source>Rev Assoc Med Bras</source><year>2006</year><volume>52</volume><fpage>148</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">16847520</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aprahamian</surname><given-names>I</given-names></name><name><surname>Martinelli</surname><given-names>J E</given-names></name><name><surname>Yassuda</surname><given-names>M S</given-names></name></person-group><article-title>Alzheimer: revis&#x000e3;o da epidemiologia e
diagn&#x000f3;stico</article-title><source>Rev Bras Clin Med</source><year>2009</year><volume>7</volume><fpage>2</fpage><lpage>2</lpage></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forlenza</surname><given-names>OV</given-names></name></person-group><article-title>Tratamento farmacol&#x000f3;gico da doen&#x000e7;a de
Alzheimer</article-title><source>Rev Psiquiatr Clin</source><year>2005</year><volume>32</volume><fpage>137</fpage><lpage>148</lpage></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>E Jr</given-names></name><name><surname>Caramelli</surname><given-names>P</given-names></name><name><surname>Nitrini</surname><given-names>R</given-names></name></person-group><article-title>Estudo epidemiol&#x000f3;gico populacional de dem&#x000ea;ncia na
cidade de Catanduva, estado de S&#x000e3;o Paulo</article-title><source>Rev Psiq Clin</source><year>1998</year><volume>25</volume><fpage>70</fpage><lpage>73</lpage></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaduszkiewicz</surname><given-names>H</given-names></name><name><surname>Hans</surname><given-names>TZ</given-names></name><name><surname>Bornholdt</surname><given-names>PB</given-names></name><name><surname>Bussche</surname><given-names>HV</given-names></name></person-group><article-title>Cholinesterase inhibitors for patients with Alzheimer's disease:
systematic review of randomised clinical trials</article-title><source>BMJ</source><year>2005</year><volume>321</volume><fpage>331</fpage><lpage>331</lpage></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vale</surname><given-names>FAC</given-names></name><name><surname>Correa-Neto</surname><given-names>Y</given-names></name><name><surname>Bertolucci</surname><given-names>PHF</given-names></name><etal/></person-group><article-title>Treatment of Alzheimer's disease in Brazil: I. Cognitive
disorders</article-title><source>Dement Neuropsychol</source><year>2011</year><volume>5</volume><fpage>177</fpage><lpage>178</lpage></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Minist&#x000e9;rio da Sa&#x000fa;de (BR)</collab><collab>Secretaria de Politicas de Sa&#x000fa;de</collab><collab>Departamento de Sistemas e Rede Assistenciais</collab></person-group><source>Protocolos Clinicos e Diretrizes Terap&#x000ea;uticas: Medicamentos
Excepcionais</source><publisher-loc>Bras&#x000ed;lia</publisher-loc><year>2002</year></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanct&#x000f4;t</surname><given-names>KL</given-names></name><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Yau</surname><given-names>KK</given-names></name><etal/></person-group><article-title>Efficacy and safety of cho-linesterase inhibitors in Alzheimer's
disease: a meta-analysis</article-title><source>CMAJ</source><year>2003</year><volume>169</volume><fpage>557</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">12975222</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockwood</surname><given-names>K</given-names></name></person-group><article-title>Size of the treatment effect on cognition of cholinesterase
inhibition in Alzheimer's disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2004</year><volume>75</volume><fpage>677</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">15090558</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelhardt</surname><given-names>E</given-names></name><name><surname>Brucki</surname><given-names>SMT</given-names></name><name><surname>Cavalcanti</surname><given-names>JLS</given-names></name><name><surname>Forlenza</surname><given-names>OV</given-names></name><name><surname>Laks</surname><given-names>J</given-names></name><name><surname>Vale</surname><given-names>FAC</given-names></name></person-group><article-title>Tratamento da doen&#x000e7;a de Alzheimer:
recomenda&#x000e7;&#x000f5;es e sugest&#x000f5;es do Departamento Cientifico de
Neurologia Cognitiva do Envelhecimento da Academia Brasileira de
Neurologia</article-title><source>Arq Neuropsiquiatr</source><year>2005</year><volume>63</volume><fpage>1104</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">16400437</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Brasil</collab></person-group><article-title>Portaria GM/MS n&#x000ba; 703, de 12 de abril de 2002 Disp&#x000f5;e sobre
a institui&#x000e7;&#x000e3;o do Programa de Assist&#x000ea;ncia aos Portadores
da Doen&#x000e7;a de Alzheimer no &#x000e2;mbito do Sistema &#x000da;nico de
Sa&#x000fa;de e d&#x000e1; outras provid&#x000ea;ncias</article-title><source>Di&#x000e1;rio Oficial da Rep&#x000fa;blica Federativa do Brasil</source><publisher-loc>Bras&#x000ed;lia</publisher-loc><day>16</day><month>4</month><year>2002</year></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Brasil</collab></person-group><source>Portaria SAS/MS n&#x000ba; 843, de 06 de novembro de 2002 Aprova o Protocolo
Clinico e Diretrizes Terap&#x000ea;uticas - Dem&#x000ea;ncia por Doen&#x000e7;a
de Alzheimer - Rivastigmina, Galantamina e Donepezil e d&#x000e1; outras
provid&#x000ea;ncias</source><publisher-name>Oficial da Rep&#x000fa;blica Federativa do
Brasil</publisher-name><publisher-loc>Brasilia</publisher-loc><day>06</day><month>11</month><year>2002</year></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="legal-doc"><person-group person-group-type="author"><collab>Brasil</collab></person-group><source>Portaria GM/ n&#x000ba; 981, de 26 de novembro de 2009. Altera a
denomina&#x000e7;&#x000e3;o do Componente de Medicamentos de
Dispensa&#x000e7;&#x000e3;o Excepcional descrito no inciso III, art. 24&#x000ba; ,
se&#x000e7;&#x000e3;o IV, da Portaria n&#x000ba; . 204/ GM</source><day>29</day><month>1</month><year>2007</year><comment>Componente Especializado da Assist&#x000ea;ncia
Farmac&#x000ea;utica</comment></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folsteln</surname><given-names>MF</given-names></name><name><surname>Folsteln</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name></person-group><article-title>O mlnl-estado mental: um m&#x000e9;todo pr&#x000e1;tico para a
classifica&#x000e7;&#x000e3;o dos pacientes estado cognitivo para o
cl&#x000ed;nico</article-title><source>J Psychiatr Res</source><year>1975</year><volume>12</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">1202204</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolucci</surname><given-names>PHF</given-names></name><etal/></person-group><article-title>O mini-exame do estado mental em uma popula&#x000e7;&#x000e3;o
geral. Impacto da escolaridade</article-title><source>Arq Neuropsiquiatr</source><year>1994</year><volume>52</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8002795</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>The ICD-10 Classification of Mental and Behavioral Disorders: Diagnostic
Criteria for Research</source><publisher-loc>Geneva, Switzerland</publisher-loc><publisher-name>World Health Organization</publisher-name><year>1993</year><fpage>36</fpage><lpage>40</lpage></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical diagnosis of Alzheimer's disease: report of the
NINCDS-ADRDA work group under the auspices of department of Health and Human
Services Task Force on Alzheimer's disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">6610841</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gauthier</surname><given-names>L</given-names></name><name><surname>G&#x000e9;linas</surname><given-names>I</given-names></name><name><surname>McIntyre</surname><given-names>M</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Laberge</surname><given-names>H</given-names></name><name><surname>Dauphinee</surname><given-names>SW</given-names></name></person-group><source>Disability Assessment for Dementia (DAD) user's guide</source><year>1994</year></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000e9;linas</surname><given-names>I</given-names></name><name><surname>Gauthier</surname><given-names>L</given-names></name><name><surname>McIntyre</surname><given-names>M</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name></person-group><article-title>Development of a functional measure for persons with Alzheimer's
disease: the disability assessment for dementia</article-title><source>Am J Occup Ther</source><year>1999</year><volume>53</volume><fpage>471</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">10500855</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carthery-Goulart</surname><given-names>M T</given-names></name></person-group><article-title>Adapta&#x000e7;&#x000e3;o transcultural da escala de
avalia&#x000e7;&#x000e3;o de incapacidade em dem&#x000ea;ncia (Disability
Assessment For Dementia -DAD)</article-title><source>Arq Neuropsiquiatr</source><year>2007</year><volume>65</volume><fpage>916</fpage><lpage>919</lpage><pub-id pub-id-type="pmid">17952309</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahia</surname><given-names>VS</given-names></name></person-group><article-title>Subdiagn&#x000f3;stico da degenera&#x000e7;&#x000e3;o lobar
frontotemporal no Brasil</article-title><source>Dement Neuropsychol</source><year>2007</year><volume>1</volume><fpage>361</fpage><lpage>365</lpage></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Sauter</surname><given-names>A</given-names></name><name><surname>Donald</surname><given-names>A</given-names></name><etal/></person-group><article-title>The disability assessment for dementia scale: a 12-month study of
functional ability in mild to moderate severity Alzheimer
disease</article-title><source>Alzheimer Dis Assoc Disord</source><year>2001</year><volume>15</volume><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">11391090</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Anuncia&#x000e7;&#x000e3;o</surname><given-names>LFC</given-names></name><name><surname>Monteiro</surname><given-names>AMF</given-names></name><name><surname>Barreto</surname><given-names>RC</given-names></name></person-group><source>Doen&#x000e7;a de Alzheimer: do diagn&#x000f3;stico cl&#x000ed;nico a
CID-10</source><comment>Dispon&#x000ed;vel em: <ext-link ext-link-type="uri" xlink:href="http://www.centronati.com/doenca-de-alzheimer-do-diagnostico-clinico-a-CID-10">http://www.centronati.com/doenca-de-alzheimer-do-diagnostico-clinico-a-CID-10</ext-link></comment></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Lemos</surname><given-names>CA</given-names></name><name><surname>Rocha</surname><given-names>EA</given-names></name><name><surname>Papaleo</surname><given-names>SS</given-names></name><name><surname>Maia</surname><given-names>EMC</given-names></name><name><surname>Pires</surname><given-names>IAH</given-names></name></person-group><source>Cuidadores de idosos com Doen&#x000e7;a de Alzheimer: capacidade
funcional do idoso "versus" avalia&#x000e7;&#x000e3;o da sobrecarga do
cuidado</source><conf-name>Anais do III Congresso Ibero-americano de
Psicogerontologia</conf-name><conf-date>2008</conf-date><comment>Dispon&#x000ed;vel em: <ext-link ext-link-type="uri" xlink:href="http://www.geracoes.org.br/arquivos._dados/foto_alta/arquivo_1_id-114.pdf">http://www.geracoes.org.br/arquivos._dados/foto_alta/arquivo_1_id-114.pdf</ext-link></comment></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>Keage</surname><given-names>HAD</given-names></name><etal/></person-group><article-title>Education, the brain and dementia: neuroprotection or
compensation?</article-title><source>Brain</source><year>2010</year><volume>133</volume><fpage>2210</fpage><lpage>2216</lpage><pub-id pub-id-type="pmid">20826429</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>LE</given-names></name><name><surname>Scherr</surname><given-names>PA</given-names></name><name><surname>Beckett</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Relation of Smoking and Alcohol Consumption to Incident
Alzheimer's Disease</article-title><source>Am J Epidemiol</source><year>1995</year><volume>135</volume><fpage>347</fpage><lpage>355</lpage></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemos</surname><given-names>ND</given-names></name><name><surname>Gazzola</surname><given-names>JM</given-names></name><name><surname>Ramos</surname><given-names>LR</given-names></name></person-group><article-title>Cuidando do Paciente com Alzheimer: o impacto da doen&#x000e7;a no
cuidador</article-title><source>Sa&#x000fa;de e Sociedade</source><year>2006</year><volume>15</volume><fpage>170</fpage><lpage>179</lpage></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jorm</surname><given-names>AF</given-names></name></person-group><source>The epidemiology of Alzheimer's disease and related disorders</source><year>1990</year><publisher-loc>London</publisher-loc><publisher-name>Shapman and Hall</publisher-name></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>LE</given-names></name><name><surname>Scherr</surname><given-names>PA</given-names></name><name><surname>McCann</surname><given-names>JJ</given-names></name><name><surname>Beckett</surname><given-names>LA</given-names></name><name><surname>Evans</surname><given-names>DA</given-names></name></person-group><article-title>Is the risk of developing Alzheimer's disease greater for women
than for men</article-title><source>Am J Epidemiol</source><year>2001</year><volume>153</volume><fpage>132</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">11159157</pub-id></element-citation></ref></ref-list></back></article>